Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional StockBusiness Wire • 05/14/21
Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 04/29/21
Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare ConferenceBusiness Wire • 04/22/21
Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation DeviceBusiness Wire • 03/02/21
Axonics Modulation Technologies' (AXNX) CEO Raymond Cohen on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/27/21
Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®Business Wire • 02/25/21
Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021Business Wire • 02/22/21
Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter MeetingBusiness Wire • 02/18/21
Axonics® Receives FDA Approval for Third-Generation Implantable NeurostimulatorBusiness Wire • 02/16/21
Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® SystemBusiness Wire • 11/10/20
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen On Q3 2020 Results - Quick Earnings Call TranscriptSeeking Alpha • 11/05/20